Suchergebnisse - "Fizazi, Karim"

PubPharm (591)

1

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel : The PACAP Study

enthalten in: European urology oncology | 2024

von Flippot, R. | Telli, T. | Velev, M. | +26

2

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer : Analyses of the Randomized Phase 3 ARASENS Study

enthalten in: European urology | 2024

von Saad, F. | Hussain, M. | Tombal, B. | +15

3

Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer : Results from the IGCCCG Update Consortium

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Bührer, E. | D'Haese, D. | Daugaard, G. | +32

4

Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer

enthalten in: Current oncology reports | 2024

von Grisay, G. | Lavaud, P. | Fizazi, K.

5

TALAPRO-3 clinical trial protocol : phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer

enthalten in: Future oncology (London, England) | 2024

von Agarwal, N. | Saad, F. | Azad, A. | +8

6

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial

enthalten in: The oncologist | 2024

von Shore, N. | Hussain, M. | Saad, F. | +10

7

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer : Patient Preference and Cognitive Function in ODENZA

enthalten in: European urology | 2024

von Colomba, E. | Jonas, S. | Eymard, J. | +21

8

Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer

enthalten in: European urology | 2024

von Chi, K. | Armstrong, A. | Krause, B. | +15

9

Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS

enthalten in: The oncologist | 2024

von Shore, N. | Gratzke, C. | Feyerabend, S. | +24

10

Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA

enthalten in: JCO clinical cancer informatics | 2024

von Carrot, A. | Oudard, S. | Colomban, O. | +5

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[60]